Lanreotide supply disruption
Supply issues at partner site will reduce Q3 lanreotide sales significantly; recovery depends on partner's production ramp-up.
high · management_commentaryCipla Ltd — Q2 FY25
Cipla reported Q2 FY25 revenue of INR 7,051 crore (+9% YoY) and an EBITDA margin of 26.7% (highest ever, +70bps YoY), driven by strong profitability in India chronic therapies a...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Goa facility FDA classification uncertainty
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
high · management_commentaryUS generic pricing erosion
Blended US price erosion of ~10% YoY, with potential for further pressure from new competition in Albuterol and other products.
medium · analyst_questionIndia acute season weakness
Slow seasonal growth in acute category, especially anti-infectives, impacted India business; recovery dependent on respiratory season.
medium · data_observation